Heading East: Biopharma International Expansion to China and Asia
December 17, 2018
China’s rapidly growing economy has helped drive unprecedented growth in its healthcare market. Driven by pro-innovation and pro-biotechnology policy trends, China is becoming a prime market for biopharmaceutical companies globally; nearly 90% of the firms in L.E.K.’s biopharma survey expressed interest in a China expansion. Furthermore, Asia, not only contains 60 percent of the world’s population, it also accounts for 30% of the world’s GDP and pharmaceutical spending. While recent policy reforms in China are expected to create enormous opportunities for global firms, China nevertheless remains a complicated market for emerging biotech companies and multinational corporations alike.
Download Full Comments Below
Biopharma International Expansion To China And Asia For Web
On behalf of its member organizations, Biotechnology Innovation Organization (“BIO”) respectfully submits this Comment in response to the United States Patent and Trademark Office’s (the “Patent Office” or “PTO”) February 13, 2024 Request for…
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.
China’s rapidly growing economy has helped drive unprecedented growth in its healthcare market. Driven by pro-innovation and pro-biotechnology policy trends, China is becoming a prime market for biopharmaceutical companies globally; nearly 90% of the firms in L.E.K.’s biopharma survey expressed interest in a China expansion. Furthermore, Asia, not only contains 60 percent of the world’s population, it also accounts for 30% of the world’s GDP and pharmaceutical spending.
While recent policy reforms in China are expected to create enormous opportunities for global firms, China nevertheless remains a complicated market for emerging biotech companies and multinational corporations alike.